PRESS RELEASE: Marinomed Biotech AG announces positive data demonstrating Carragelose efficacy against SARS-CoV-2 variants
04/21/2021 | 01:46am EDT
Send by mail :
Message :
Required fields
DGAP-News: Marinomed Biotech AG / Key word(s): Study
Marinomed Biotech AG announces positive data demonstrating Carragelose efficacy against SARS-CoV-2 variants
2021-04-21 / 07:45
The issuer is solely responsible for the content of this announcement.
=
Marinomed Biotech AG announces positive data demonstrating Carragelose efficacy against SARS-CoV-2 variants . Carragelose inactivates common SARS-CoV-2 variants with similar efficacy as wildtype virus in vitro . Efficacy against wildtype SARS-CoV-2 is clinically proven^[1] . COVID-19 pandemic currently mostly driven by three SARS-CoV-2 variants, B.1.1.7, B.135.1 and P1 (also known as